Our approach to science

PharmaMar is conducting a multi-phase research program to discover and develop new antitumor compounds of marine origin. We have over 1200 patents issued.

R&D at PharmaMar is a mix of
science innovation and experimentation

How do we do R&D at PharmaMar

How do we do R&D at PharmaMar

We're a unique kind of pharma company

We are inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. We intend to continue to be the world leader in marine medicinal discovery, development and innovation.

- Global marine expeditions finding new organisms
- Screen for anti-cancer properties
- Isolate, refine, synthesize, prioritize
- Robust in vitro and in vivo testing

We're a unique kind of pharma company

From seaside to bedside

PharmaMar conducts basic research with marine expeditions, compound isolation, chemical synthesis, in vivo and in vitro studies to discover and develop new antitumor compounds of marine origin.

The marine expeditions are in accordance with all laws and ecological regulations of various governments, NGOs and others, and our extraction process involves extremely small sample sizes harvested by hand.

Mechanism of action for our commercial and clinical assets

TRABECTEDIN

LURBINECTEDIN

PLITIDEPSIN

ECUBECTEDIN

TRABECTEDIN

Trabectedin, also known as ecteinascidin 743 or ET-743, or commercially where it is approved as Yondelis® is a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata.

Trabectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis.

LURBINECTEDIN

Lurbinectedin, also known as PM01183, or commercially where approved as Zepzelca® is an analogue of a similar natural compound ET-736 with characteristics that make it similar but different to its parent compounds.

Lurbinectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis.

PLITIDEPSIN

Plitidepsin, also known as PM90001, or Aplidin® in Australia where it is approved for multiple myeloma, is a synthetic compound originally inspired by ascidian Aplidium albicans, a tunicate.

Its mechanism of action is as an inhibitor of the eukaryotic translation eEF1A. In cancer cells this ultimately leads to cell-cycle arrest, growth inhibition and induction of apoptosis via multiple pathway alterations.

ECUBECTEDIN

Ecubectedin, also known as PM14, is a synthetic analog from the medicinal chemistry program of lurbinectedin.

Ecubectedin is a compound that acts by specifically inhibiting RNA synthesis and active transcription of protein-coding genes

TRABECTEDIN

TRABECTEDIN

Trabectedin, also known as ecteinascidin 743 or ET-743, or commercially where it is approved as Yondelis® is a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata.

Trabectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis.

LURBINECTEDIN

LURBINECTEDIN

Lurbinectedin, also known as PM01183, or commercially where approved as Zepzelca® is an analogue of a similar natural compound ET-736 with characteristics that make it similar but different to its parent compounds.

Lurbinectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis.

PLITIDEPSIN

PLITIDEPSIN

Plitidepsin, also known as PM90001, or Aplidin® in Australia where it is approved for multiple myeloma, is a synthetic compound originally inspired by ascidian Aplidium albicans, a tunicate.

Its mechanism of action is as an inhibitor of the eukaryotic translation eEF1A. In cancer cells this ultimately leads to cell-cycle arrest, growth inhibition and induction of apoptosis via multiple pathway alterations.

ECUBECTEDIN

ECUBECTEDIN

Ecubectedin, also known as PM14, is a synthetic analog from the medicinal chemistry program of lurbinectedin.

Ecubectedin is a compound that acts by specifically inhibiting RNA synthesis and active transcription of protein-coding genes

VIROLOGY UNIT

Currently, we are examining in clinical trials a potential Covid-19 treatment

Treat new pandemics

that could descend upon the world again

Discover Our Virology Unit

To learn more about viruses

a how to improve responses to them

To treat

current patients with Covid-19

We keep innovating through Cofinanced Projects

PharmaMar’s research efforts have been recognized through grants from public entities for several projects, both individual and in cooperation with public centers and private companies. These collaborative projects aim to make the maximum use of human and technical resources, searching for synergies that permit a greater progress in innovation and a positive impact on society.

The public funding comes mainly from the Centro de Desarrollo Tecnológico Industrial (CDTI) and the State Agency for Research (part of the Ministry of Science and Innovation) as well as from the Framework Programs of the European Union.

0.3483 seconds.